近日，浙江九洲药业股份有限公司（以下简称"公司"）全资子公司九洲生 物医药（台州）有限公司（原"浙江四维医药科技有限公司"）收到国家药品监 督管理局（以下简称"国家药监局"）核准签发的甲苯磺酸艾多沙班片的《药品 注册证书》，具体情况如下： 一、药品的基本情况 证券代码：603456 证券简称：九洲药业 公告编号：2025-067 浙江九洲药业股份有限公司 关于全资子公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 生产单位：九洲生物医药（台州）有限公司 生产地址：浙江省台州市椒江区海门街道滨海路 59 号 药品名称：甲苯磺酸艾多沙班 剂型：片剂 规格：60mg、30mg 申请事项：药品注册（境内生产） 注册分类：化学药品 4 类 批准文号：国药准字 H20255929、国药准字 H20255930 批准文号有效期：至 2030 年 11 月 11 日 上市许可持有人：九洲生物医药（台州）有限公司 上市许可持有人地址：浙江省台州市椒江区海门街道滨海路 59 号 审批结论：根据《中华人民共和国药品管理法》 ...

Core Viewpoint - The company has received approval for the registration certificate of Tofacitinib Tosylate Tablets, enhancing its product pipeline and market competitiveness [1] Group 1: Product Approval - The company's wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has obtained the drug registration certificate from the National Medical Products Administration for Tofacitinib Tosylate Tablets [1] - Tofacitinib Tosylate is an oral anticoagulant primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Market Impact - The acquisition of the drug registration certificate will further enrich the company's product pipeline and help enhance its market competitiveness [1] - The recent approval is not expected to have a significant short-term impact on the company's performance [1] Group 3: Industry Characteristics - The production and sales of pharmaceutical products are influenced by market conditions, industry policies, and supply-demand relationships, which introduces a degree of uncertainty [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) announced that its wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has received the drug registration certificate for Edoxaban Tosilate Tablets from the National Medical Products Administration [1] Group 1: Company Developments - Jiuzhou Biopharmaceutical has been granted approval for Edoxaban Tosilate, an oral anticoagulant [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] - Edoxaban Tosilate was originally developed by Daiichi Sankyo in Japan and was launched in Japan in April 2011 [1] Group 2: Industry Context - Other manufacturers in China that have obtained registration for Edoxaban include Hainan Sinopharm and Shandong New Era Pharmaceutical [1]

Core Viewpoint - Jiuzhou Pharmaceutical (603456.SH) has received approval from the National Medical Products Administration for the registration of Tofisopam Tosylate Tablets, marking a significant milestone for the company in the oral anticoagulant market [1] Group 1: Company Developments - Jiuzhou Pharmaceutical's wholly-owned subsidiary, Jiuzhou Biopharmaceutical (Taizhou) Co., Ltd., has been granted the Drug Registration Certificate for Tofisopam Tosylate Tablets [1] - The drug is primarily used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, as well as for the treatment or prevention of deep vein thrombosis and pulmonary embolism [1] Group 2: Industry Context - Tofisopam Tosylate was originally developed by Daiichi Sankyo in Japan and was launched in April 2011 [1] - Other manufacturers in China that have obtained registration for this drug include Hainan Xiansheng Pharmaceutical Co., Ltd. and Shandong New Era Pharmaceutical Co., Ltd. [1]

Core Viewpoint - Jiuzhou Pharmaceutical has seen a significant stock price increase, with a 5.31% rise on November 14, reaching 21.42 yuan per share, and a total market capitalization of 19.052 billion yuan, indicating strong investor interest and performance in the market [1]. Company Overview - Jiuzhou Pharmaceutical, established on July 13, 1998, and listed on October 10, 2014, is located in Taizhou, Zhejiang Province. The company specializes in the research, production, and sales of chemical raw materials and pharmaceutical intermediates [1]. - The revenue composition of Jiuzhou Pharmaceutical includes 79.81% from new drug custom development and manufacturing services (CDMO), 18.22% from specialty raw materials and intermediates, and 1.96% from other sources [1]. Shareholder Insights - Among the top circulating shareholders of Jiuzhou Pharmaceutical, a fund under China Europe Fund has increased its holdings. The China Europe Medical Health Mixed A Fund (003095) added 3.9767 million shares in the third quarter, bringing its total to 17.403 million shares, which represents 1.96% of the circulating shares [2]. - The fund has realized a floating profit of approximately 18.7952 million yuan today, with a total floating profit of 15.8367 million yuan during the four-day stock price increase [2]. Fund Manager Performance - The fund manager of China Europe Medical Health Mixed A, Ge Lan, has a tenure of 10 years and 293 days, with a total fund size of 43.544 billion yuan. The best return during her tenure is 109.26%, while the worst is -35.13% [3]. - Co-manager Zhao Lei has been in position for 134 days, managing a fund size of 32.954 billion yuan, with a best return of 8.82% and a worst return of 8.51% during his tenure [3].

Core Points - The ownership structure of Jiuzhou Pharmaceutical has changed, with Huaxuande no longer holding shares in Zhongbei Group and Taizhou Gede, leading to a new actual controller structure involving Huali Rong and Huaxiao Hui [2][3] - Jiuzhou Pharmaceutical reported a revenue of 4.16 billion yuan for the first three quarters of the year, reflecting a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4] Group 1 - Huaxuande transferred 28.50% of Zhongbei Group's shares to Huali Rong and 14% to Huaxiao Hui, with total payments amounting to 61.815 million yuan [2] - Following the transfer, Huali Rong holds 22.17% and Huaxiao Hui holds 13.36% of Jiuzhou Pharmaceutical indirectly [2] - The market value of Jiuzhou Pharmaceutical shares held by Zhongbei Group and Taizhou Gede is estimated at approximately 24.76 billion yuan [2] Group 2 - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [3] - Huaxuande, aged 82, stepped down as chairman in 2014, with his daughter Huali Rong succeeding him [3] - Huali Rong has held various leadership roles and was recently elected as the executive director and legal representative of Jiuzhou Pharmaceutical [3] Group 3 - Huaxuande and his family's wealth was ranked 338th on the Hurun Rich List in 2020 with 16 billion yuan, and they are currently ranked 2750th and 940th on the global and national rich lists, respectively [4] - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [4]

Core Viewpoint - The control of Jiuzhou Pharmaceutical has changed due to the transfer of shares from the aging actual controller, Hua Xuande, to his daughters, Hua Lirong and Hua Xiaohui, which will not affect the company's operational independence or business performance [2][4]. Group 1: Share Transfer Details - Hua Xuande transferred 42.50% of his shares in Zhongbei Group and 10.00% in Taizhou Gede to his daughters, with Hua Lirong receiving 28.50% and Hua Xiaohui 14% of Zhongbei Group, and each receiving 5% of Taizhou Gede [1]. - The total payment for the share transfer was 61.815 million yuan, with Hua Lirong paying 41.333 million yuan and Hua Xiaohui 20.482 million yuan [1]. - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's closing price of 19.88 yuan per share, is approximately 2.476 billion yuan [1]. Group 2: Company Background and Performance - Jiuzhou Pharmaceutical, established in July 1998, is a technology-driven CDMO enterprise focusing on small molecule chemical drugs, peptide drugs, conjugated drugs, and small nucleic acid drugs [4]. - The company reported a revenue of 4.16 billion yuan for the first three quarters of the year, representing a year-on-year growth of 4.92%, and a net profit of 748 million yuan, up 18.51% year-on-year [4]. - As of November 13, Jiuzhou Pharmaceutical's stock price increased by 2.11% to 20.34 yuan per share, with a market capitalization of 18.091 billion yuan [5].

其中，28.50%中贝集团股权转让给花莉蓉，14%转让给花晓慧；台州歌德股权由花莉蓉、花晓慧各自受 让5%。花莉蓉、花晓慧受让上述股权支付的对价分别为4133.3万元、2048.2万元。 此次调整后，公司控股股东未发生变化，花轩德将不再持有中贝集团、台州歌德的股权，同时不再间接 持有上市公司股票。花莉蓉将直接持有中贝集团51.00%股权、台州歌德5.00%股权；花晓慧将直接持有 中贝集团36.50%股权、台州歌德5.00%股权。 【#82岁富豪将近25亿元股票分给两女#，花轩德拟彻底退隐】 据红星资本局报道，11月12日，九洲药业昨日公告称，公司于近日收到控股股东浙江中贝九洲集团（下 称"中贝集团"）及其一致行动人台州歌德的《告知函》，花轩德因年事已高，拟将其持有的中贝集团 42.50%股权、台州歌德10%股权转让给女儿花莉蓉和花晓慧。 截至目前，中贝集团、台州歌德分别持有九洲药业股票2.8352亿股、4058.568万股。以九洲药业截至11 月11日的收盘价（19.88元/股）估算，上述股票对应的市值分别为56.36亿元、8.07亿元。以此估算，花 轩德转让的两笔股权间接持有九洲药业股票的市值合计约24.7 ...

Core Viewpoint - The actual controller of Jiuzhou Pharmaceutical has changed as Huaxuande transfers his shares to his daughters, resulting in a shift in control to them due to Huaxuande's advanced age [1][9]. Shareholding Structure - Huaxuande transferred 42.5% of his shares in Zhejiang Zhongbei Jiuzhou Group and 10% in Taizhou Gede Industrial to his daughters, with Huaxuande no longer holding any shares post-transfer [3][9]. - After the transfer, Huaxuande's daughters hold 22.17% and 13.36% of Jiuzhou Pharmaceutical, respectively, while Huaxuande exits the role of actual controller [1][9]. Financial Details - The total consideration for the share transfer was approximately 61.115 million yuan for Zhongbei Group and 700,000 yuan for Taizhou Gede [9]. - The estimated market value of the shares transferred, based on Jiuzhou Pharmaceutical's stock price of 20.23 yuan per share, is approximately 2.5191 billion yuan [7][9]. Background Information - Huaxuande, born in 1943, is the founder of Jiuzhou Pharmaceutical and has gradually stepped back from management roles due to age, having resigned from key positions since 2017 [11][12]. - Jiuzhou Pharmaceutical transitioned from producing chemical raw materials to contract custom development and production since 2008, and it was listed on the Shanghai Stock Exchange in 2014 [11].

Group 1 - The board of directors of Zhejiang Jiuzhou Pharmaceutical Co., Ltd. held its 18th meeting of the 8th session on November 12, 2025, with all 9 directors present, confirming the legality and validity of the meeting [2][4] - The board approved the election of Ms. Hua Lirong as the representative director to execute company affairs and as the legal representative, with her term lasting until the end of the current board's term [3][4] - The board also approved the election of members for the audit committee, including Ms. Jiang Qi, Mr. Yang Lirong, and Mr. Li Jicheng, with Ms. Jiang serving as the committee's convener [5][6] Group 2 - The audit committee is composed of a majority of independent directors, complying with relevant laws and regulations [5] - The term for the newly elected audit committee members will also last until the end of the current board's term [5]